Skip to content
10-Q

Quarterly Report

Rejuvel Bio-Sciences, Inc.

0001469709-15-000291

← back to feed
Filed
May 20, 2015 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow FY 2014 · Mar 31, 2015 −$173.97K
Operating Cash Flow FY 2014 · Mar 31, 2014 −$123.86K
Cash And Equivalents FY 2014 · Mar 31, 2015 $44.19K
Cash And Equivalents FY 2014 · Mar 31, 2014 $218.31K
Stockholders Equity FY 2014 · Mar 31, 2015 −$932.28K
Current Liabilities FY 2014 · Mar 31, 2015 $1.16M
Total Liabilities FY 2014 · Mar 31, 2015 $1.16M
Current Assets FY 2014 · Mar 31, 2015 $180.45K
Total Assets FY 2014 · Mar 31, 2015 $230.08K
Sga Expense FY 2014 · Mar 31, 2015 $272.15K
Sga Expense FY 2014 · Mar 31, 2014 $128.73K
Net Income FY 2014 · Mar 31, 2015 −$244.81K
Net Income FY 2014 · Mar 31, 2014 −$2.39M
Operating Income FY 2014 · Mar 31, 2015 −$210.96K
Operating Income FY 2014 · Mar 31, 2014 −$129.38K
Gross Profit FY 2014 · Mar 31, 2015 $61.18K
Gross Profit FY 2014 · Mar 31, 2014 −$652
Cost Of Revenue FY 2014 · Mar 31, 2015 $9.17K
Cost Of Revenue FY 2014 · Mar 31, 2014 $2.92K
Revenue FY 2014 · Mar 31, 2015 $70.36K
Revenue FY 2014 · Mar 31, 2014 $2.27K